EUVIMEDEUVIMED entdecken
Crossref

Synthesis and characterization of ligustrazine-acylhydrazone derivatives and their inhibitory activity against human lung cancer A549 cells

Ting Wang

Pakistan Journal of Pharmaceutical Sciences · 01.02.2027

DOI: 10.36721/pjps/2026.40.16269.1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pakistan Journal of Pharmaceutical Sciences, online erschienen am 23.10.2026. Verfasst von Ting Wang. Die Arbeit nennt 54 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ligustrazine is a pivotal active component of Ligusticum wallichii Franch; it is used clinically for treating cardiovascular diseases. Derivatization of ligustrazine might promote its biological activities and bioavailability.

Objectives

A series of ligustrazine-acylhydrazone derivatives (TMPAD-1–TMPAD-13) were synthesized and their inhibitory activity against A549 cells was investigated.

Methods

These derivatives were synthesized by condensing aromatic aldehydes with ligustrazine-based hydrazides to form acylhydrazone bonds and their chemical structures were characterized through a combination of spectral methods, including Fourier transform infrared (FT-IR) spectroscopy, electrospray ionization high resolution mass spectrometry (ESI-HRMS), 1H and 13C nuclear magnetic resonance (NMR) spectra.

Results

In-vitro experimental results displayed that TMPAD-2 exhibited marked inhibitory activity against A549 cells as shown by impeding cell proliferation (IC50 = 48.08 μmol/L), colony formation (colony forming efficiency ≤ 1.5 ± 0.02%), invasion and migration, enhancing tumor necrosis factor (TNF)-α and reactive oxygen species (ROS) levels, decreasing interleukin (IL)-6 and mitochondrial membrane potential (MMP) levels, hindering cell cycle progression and inducing apoptosis. RNA-sequencing (RNA-seq) analysis disclosed 17 lung cancer-related differentially expressed genes (DEGs). These results were statistically supported with significant p-value.

Conclusion

These results suggest that dysregulation of the cyclin–cyclin-dependent kinase (CDK)–cyclin-dependent kinase inhibitor (CKI) regulatory network is primarily responsible for the inhibitory action of TMPAD-2 on A549 cells. Current findings might provide valuable insights for further development of ligustrazine derivatives as novel anticancer agents.

Zitieren

APA

Wang, T. (2027). Synthesis and characterization of ligustrazine-acylhydrazone derivatives and their inhibitory activity against human lung cancer A549 cells. Pakistan Journal of Pharmaceutical Sciences. https://doi.org/10.36721/pjps/2026.40.16269.1

Vancouver

Wang T. Synthesis and characterization of ligustrazine-acylhydrazone derivatives and their inhibitory activity against human lung cancer A549 cells. Pakistan Journal of Pharmaceutical Sciences. 2027. doi:10.36721/pjps/2026.40.16269.1

BibTeX
@article{Wang2027,
  author = {Wang, Ting},
  title = {Synthesis and characterization of ligustrazine-acylhydrazone derivatives and their inhibitory activity against human lung cancer A549 cells},
  journal = {Pakistan Journal of Pharmaceutical Sciences},
  year = {2027},
  doi = {10.36721/pjps/2026.40.16269.1}
}
Kostenlos starten →